secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-052142
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics Q1 net loss $65.6M; cash $453.5M; clinical trials on track for H2 data
--------------------------------------------------------------------------------

- Net loss $65.6M ($0.81 per share) vs $44.2M ($0.78) in Q1 2023.
- Cash, equivalents and marketable securities $453.5M; expects funding through 2025.
- R&D expenses $44.5M (up 19% YoY); G&A expenses $24.6M (up 211% YoY) largely due to new CEO.
- John Cox appointed CEO and President in March 2024.
- Phase 1/2 ACHIEVE (DM1) and DELIVER (DMD) trials progressing; additional data expected H2 2024 with registrational cohorts by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017024052142/0000950170-24-052142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017024052142/dyn-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-052142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer